Want to see JP:7096 full AI Analyst Report?
Top Page
StemCell Institute
(7096)
Select Model
Select Model
Rating:47Neutral
Price Target:
¥738.00
▼(-6.94% Downside)
Action:Reiterated
Date:05/15/26
The score is held back most by deteriorating cash flow and sharply weaker 2026 profitability, alongside a bearish technical trend. A generally healthy balance sheet and solid gross margin provide some support, but the high P/E leaves limited valuation cushion.
Positive Factors
Revenue growth trend
Consistent multi-year revenue growth indicates durable end-market demand and ongoing product adoption. That steady top-line base supports predictable scale benefits, helps absorb cyclical pressures, and improves visibility for planning and investment decisions over the next 2–6 months.
Negative Factors
Deteriorating cash generation
Sharp OCF decline and deeply negative free cash flow materially weaken self-funding ability. This increases dependence on external capital, raises dilution or covenant risk, and constrains discretionary spending (commercialization, trials) — a structural constraint on execution over months ahead.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue growth trend
Consistent multi-year revenue growth indicates durable end-market demand and ongoing product adoption. That steady top-line base supports predictable scale benefits, helps absorb cyclical pressures, and improves visibility for planning and investment decisions over the next 2–6 months.
Read all positive factors
StemCell Institute (7096) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥7.67B
Dividend YieldN/A
Average Volume (3M)28.64K
Price to Earnings (P/E)49.2
Beta (1Y)0.46
Revenue Growth4.93%
EPS Growth-59.57%
CountryJP
Employees98
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)15.24
Shares Outstanding10,246,600
10 Day Avg. Volume23,150
30 Day Avg. Volume28,640
Financial Highlights & Ratios
PEG Ratio-0.84
Price to Book (P/B)2.88
Price to Sales (P/S)2.75
P/FCF Ratio-23.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)19.9
Revenue Forecast (FY)¥3.18B
StemCell Institute Business Overview & Revenue Model
Company Description
StemCell Institute Inc. provides specialized stem cell banking services throughout Japan. In addition to its core preservation activities, the company is deeply involved in the research and development of medical therapies that utilize stem cells,...
How the Company Makes Money
null...
StemCell Institute Financial Statement Overview
Summary
Income Statement
64
Positive
Balance Sheet
72
Positive
Cash Flow
34
Negative
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.81B | 2.68B | 2.48B | 2.09B | 1.78B |
| Gross Profit | 1.71B | 1.69B | 1.58B | 1.34B | 1.11B |
| EBITDA | 379.99M | 695.19M | 534.00M | 402.49M | 309.47M |
| Net Income | 155.92M | 385.80M | 310.98M | 198.03M | 133.73M |
Balance Sheet | |||||
| Total Assets | 8.12B | 7.52B | 6.59B | 5.83B | 5.23B |
| Cash, Cash Equivalents and Short-Term Investments | 2.83B | 3.20B | 2.85B | 3.32B | 3.51B |
| Total Debt | 473.81M | 518.96M | 10.78M | 5.89M | 0.00 |
| Total Liabilities | 5.05B | 4.89B | 3.90B | 3.53B | 3.13B |
| Stockholders Equity | 2.68B | 2.63B | 2.69B | 2.30B | 2.10B |
Cash Flow | |||||
| Free Cash Flow | -335.78M | -10.11M | 132.97M | 39.77M | 264.81M |
| Operating Cash Flow | 73.51M | 467.69M | 334.63M | 99.67M | 469.29M |
| Investing Cash Flow | -337.92M | -259.08M | -811.77M | -285.10M | 404.17M |
| Financing Cash Flow | -175.09M | 146.70M | -1.33M | -869.00K | 644.37M |
StemCell Institute Technical Analysis
Neutral
793.00
Price Trends
694.20
Positive
748.48
Positive
789.61
Negative
Market Momentum
19.38
Negative
59.69
Neutral
54.62
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7096, the sentiment is Neutral. The current price of 793 is above the 20-day moving average (MA) of 735.30, above the 50-day MA of 694.20, and above the 200-day MA of 789.61, indicating a neutral trend. The MACD of 19.38 indicates Negative momentum. The RSI at 59.69 is Neutral, neither overbought nor oversold. The STOCH value of 54.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:7096.
StemCell Institute Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
50 Neutral | ¥25.22B | -34.36 | ― | ― | -11.11% | -187.80% | |
49 Neutral | ¥18.43B | -9.94 | ― | ― | ― | 6.10% | |
47 Neutral | ¥7.67B | 49.21 | ― | ― | 4.93% | -59.57% | |
45 Neutral | ¥12.35B | -20.03 | ― | ― | -25.02% | -697.06% | |
43 Neutral | ¥34.56B | -10.50 | ― | ― | -87.41% | 43.60% | |
42 Neutral | ¥8.61B | -7.90 | ― | ― | -62.06% | 7.56% |
* General Sector Average
JP:7096
StemCell Institute
731.00
-276.00
-27.41%
JP:4593
Healios KK
261.00
-452.00
-63.39%
JP:4599
StemRIM Inc.
299.00
-5.00
-1.64%
JP:4978
ReproCELL Inc.
127.00
-70.00
-35.53%
JP:7774
Japan Tissue Engineering Co., Ltd.
622.00
-6.00
-0.96%
JP:7776
CellSeed Inc.
219.00
-252.00
-53.50%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.